TYRA
Tyra Biosciences Inc (TYRA)
Healthcare • NASDAQ • $34.32+4.32%
- Symbol
- TYRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $34.32
- Daily Change
- +4.32%
- Market Cap
- $2.04B
- Trailing P/E
- N/A
- Forward P/E
- -13.37
- 52W High
- $40.65
- 52W Low
- $8.75
- Analyst Target
- $51.24
- Dividend Yield
- N/A
- Beta
- 0.79
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYR…
Company websiteResearch TYRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.